Welcome to our dedicated page for Organogenesis Holdings SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Organogenesis Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Organogenesis Holdings's regulatory disclosures and financial reporting.
Organogenesis Holdings Inc. vice president of strategy Robert Cavorsi reported three tax-withholding dispositions of Class A Common Stock tied to equity compensation. On February 15, 2026, he delivered 6,667, 5,549 and 5,442 shares at $3.73 per share to cover tax obligations, and continued to hold a substantial direct stake afterward.
Organogenesis Holdings Inc. reported insider tax-related share dispositions by Chief Administrative and Legal Officer Lori Freedman. On February 15, 2026, she executed four Form 4 code F transactions in Class A common stock, delivering 4,043, 24,428, 12,761 and 13,510 shares at $3.73 per share to cover tax liabilities. Following these non-open-market transactions, she held 791,717 shares directly.
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported several tax-related share dispositions of Class A Common Stock. On February 15, 2026, he delivered an aggregate of 271,406 shares at $3.73 per share to satisfy tax withholding obligations. Following these transactions, he directly owned 3,243,917 Class A Common shares.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow reported four tax-withholding dispositions of Class A common stock on February 15, 2026. The transactions, coded “F” and priced at $3.73 per share, were used to satisfy tax liabilities and left him with 628,418 shares held directly.
Organogenesis Holdings Inc. vice president of health policy Antonio S. Montecalvo reported four tax-withholding dispositions of Class A Common Stock on February 15, 2026. A total of 18,619 shares were delivered at $3.73 per share to cover tax obligations, leaving him with 178,061 directly owned shares.
Organogenesis Holdings Inc. received an amended Schedule 13G from institutional investor First Light Asset Management, LLC and its control person, Mathew P. Arens, reporting their current ownership in the company’s common stock.
The filing shows First Light Asset Management may be deemed to beneficially own 3,611,616 shares, representing 2.85% of Organogenesis’ common stock. Mathew P. Arens may be deemed to beneficially own 3,888,816 shares, or 3.06% of the class, including 231,000 shares he holds directly and additional shares through joint and advised accounts.
The reporting persons certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Organogenesis. Because each now reports ownership below 5% of the outstanding shares, the filing confirms they are no longer large (5%+) shareholders.
Organogenesis Holdings Inc. has a large shareholder group led by Soleus Capital reporting a significant passive stake. Through Soleus Capital Master Fund, L.P., the group beneficially owns 9,985,951 shares of common stock, representing 7.9% of the outstanding shares based on 126,912,142 shares outstanding as of October 30, 2025.
All reported shares are held directly by the Master Fund, with several Soleus-affiliated entities and Guy Levy listed because of their control roles. These parties expressly disclaim beneficial ownership outside their reporting obligations under U.S. securities law and certify the holdings were not acquired to change or influence control of Organogenesis.
Organogenesis Holdings Inc. reported an insider stock transaction by a company director. On 12/16/2025, the director sold 200,000 shares of Class A Common Stock in open-market trades at a weighted-average price of $5.1353 per share, with individual trade prices ranging from $5.10 to $5.24.
After this sale, the director directly beneficially owns 2,565,591 shares of Class A Common Stock. In addition, the director has indirect beneficial ownership through three trusts holding 918,680 shares, 7,928,570 shares, and 335,719 shares of Class A Common Stock, respectively.
Organogenesis Holdings Inc. reported Q3 2025 results showing stronger profitability. Total revenue was $150.864M (net product revenue $150.487M), up from $115.177M a year ago. Income from operations rose to $20.727M, and net income reached $21.567M, or $0.11 per diluted share. Advanced Wound Care drove the quarter with $141.451M, while Surgical & Sports Medicine contributed $9.036M.
Year to date, revenue was $338.562M versus $355.387M in 2024, with a net loss of $6.668M. Cash and cash equivalents were $63.745M and operating cash flow was an outflow of $49.729M for the nine months. Accounts receivable increased to $168.783M and inventories to $39.583M. The company recorded $0.603M of grant income tied to the Smithfield facility buildout and ended the quarter with deferred grant income on the balance sheet.
The revolving credit facility was reduced to $75M with updated covenants; there were no outstanding borrowings. Management flagged potential Medicare LCD changes effective January 1, 2026 that would limit coverage for several products. In clinical updates, a second Phase 3 ReNu knee OA trial did not meet its primary endpoint; an FDA meeting is scheduled for December 12, 2025 to discuss a BLA using combined data.
Organogenesis Holdings (ORGO) reported that it announced its fiscal third-quarter results for the period ended September 30, 2025, via a press release dated November 6, 2025. The company furnished the press release as Exhibit 99.1 to an 8-K.
The company stated that the press release is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. For full details, readers are directed to the furnished Exhibit 99.1.